Analyst Reco. Aligos Therapeutics, Inc.

Equities

ALGS

US01626L1052

Real-time Estimate Cboe BZX Other stock markets 02:14:22 2024-06-12 pm EDT			5-day change	1st Jan Change
0.518 ^USD	-0.58%		-13.26%	-21.69%

May. 22	Aligos Therapeutics, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors	CI
May. 21	Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2A Herald Study for the Treatment of Mash	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Adjusts Price Target on Aligos Therapeutics to $7 From $3, Maintains Overweight Rating	23-01-17	MT
Piper Sandler Upgrades Aligos Therapeutics to Overweight From Neutral, Adjusts Price Target to $3 From $2	23-01-06	MT
Jefferies Upgrades Aligos Therapeutics to Buy From Hold, Adjusts Price Target to $3 From $2.50	23-01-06	MT
SVB Securities Adjusts Aligos Therapeutics' Price Target to $2 From $3, Keeps Market Perform Rating	22-11-03	MT
Cantor Fitzgerald Downgrades Aligos Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.20 From $11	22-08-08	MT
SVB Leerink Cuts Aligos Therapeutics to Market Perform From Outperform, Price Target to $3 From $7	22-05-05	MT
Jefferies Lowers Price Target for Aligos Therapeutics to $2.50 From $5, Maintains Hold Rating	22-03-23	MT
SVB Leerink Adjusts Aligos Therapeutics' Price Target to $7 from $11, Keeps Outperform Rating	22-03-23	MT
Piper Sandler Cuts Aligos Therapeutics to Neutral From Overweight, Price Target to $4 From $15	22-03-23	MT
SVB Leerink Adjusts Aligos Therapeutics' Price Target to $11 from $10, Keeps Outperform Rating	22-03-11	MT
SVB Leerink Adjusts Aligos Therapeutics' Price Target to $10 from $15, Maintains Outperform Rating	22-02-16	MT
Jefferies Downgrades Aligos Therapeutics to Hold From Buy, Adjusts Price Target to $5 From $20	22-01-07	MT
SVB Leerink Adjusts Aligos Therapeutics' Price Target to $15 from $29, Keeps Outperform Rating	22-01-07	MT
JPMorgan Lowers Aligos Therapeutics to Neutral From Overweight, Price Target to $12 From $30	22-01-07	MT
ALIGOS THERAPEUTICS : SVB Leerink Starts Aligos Therapeutics at Outperform with $29 Price Target	21-09-09	MT
ALIGOS THERAPEUTICS : Piper Sandler Initiates Coverage on Aligos Therapeutics With Overweight Rating, $47 Price Target	21-05-17	MT
ALIGOS THERAPEUTICS : Piper Sandler Adjusts Price Target on Aligos Therapeutics to $40 From $35, Maintains Overweight Rating	21-03-24	MT
ALIGOS THERAPEUTICS : Jefferies & Co Adjusts Aligos Therapeutics PT to $30 From $26, Maintains Buy Rating	20-12-21	MT
ALIGOS THERAPEUTICS : Cantor Fitzgerald Starts Aligos Therapeutics at Overweight With $28 Price Target	20-11-10	MT
ALIGOS THERAPEUTICS : Piper Sandler Starts Aligos Therapeutics at Overweight With $35 Price Target	20-11-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Aligos Therapeutics, Inc.

Equities

ALGS

US01626L1052

Analyst Reco.

Filters